Drug firm Bharat Parenterals on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for favipiravir oral suspension, to be used for treatment of COVID-19 patients.
The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.
Favipiravir, an antiviral drug, was approved in Japan in 2014 for the treatment of novel or re-emerging influenza virus infections.
Mumbai News: Developer Accused Of Defying MHADA Orders, Families Still Await Homes In ₹7-Crore Flat Scam
VHP Launches Diwali Campaign To Clean, Light And Decorate Over 11,000 Temples In Maharashtra
Students Allege Stipend Delays, Antiquated Courses As Pune University’s NIRF Score Drops Sharply
Mumbai News: Chunabhatti Police Bust International Mobile Theft Syndicate, 8 Arrested
